Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Quest LaboratoriesNSE:QUESTLAB -2.53%44 EV-to-EBIT is 7.49 as of Jul. 19, 2026, which is 13% below its 10-year median of 8.60. GuruFocus rates NSE:QUESTLAB with a GF Score™ of 44/100. The stock has 5 warning signs investors should review. Among 689 Drug Manufacturers companies, Quest Laboratories ranks better than 81.13% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Quest Laboratories's Enterprise Value for the quarter that ended in Mar. 2026 was ₹1,661 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quest Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹200 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories EV-to-EBIT Related Terms
Quest Laboratories EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Quest Laboratories's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:QUESTLAB vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Quest Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Laboratories EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Quest Laboratories's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Quest Laboratories's EV-to-EBIT falls into.
Quest Laboratories's current Enterprise Value is ₹1,495 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Quest Laboratories's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹200 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Laboratories (NSE:QUESTLAB) has a EV-to-EBIT of 7.49 as of Jul. 19, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Quest Laboratories and its competitors. This is 13% below median its historical median of 8.60. Over the past decade, Quest Laboratories' EV-to-EBIT has ranged from 6.07 to 17.02. According to the industry distribution chart, Quest Laboratories ranks #130 out of 689 companies in the Drug Manufacturers industry, placing it in the top 18.9%.
Is Quest Laboratories' EV-to-EBIT too high?
Quest Laboratories' current EV-to-EBIT of 7.49 is 13% below median its 10-year median of 8.60. Over the past 10 years, this metric has ranged from a low of 6.07 to a high of 17.02. The Drug Manufacturers industry median EV-to-EBIT is 15.80. Quest Laboratories' value of 7.49 is 52.6% below this industry median. Based on the distribution chart, Quest Laboratories ranks #130 out of 689 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Quest Laboratories has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Quest Laboratories' EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Quest Laboratories ranks #130 out of 689 companies for EV-to-EBIT. This places Quest Laboratories in the top 19% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 15.80. Quest Laboratories' value of 7.49 is 52.6% below this benchmark. Historically, Quest Laboratories' own EV-to-EBIT has ranged from 6.07 to 17.02 over the past decade. While the company's 10-year median is 8.60 vs. the industry median of 15.80, Quest Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.80, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Quest Laboratories's current EV-to-EBIT of 7.49 is 52.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Quest Laboratories and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Quest Laboratories's current EV-to-EBIT is 7.49, which is 13% below median its own 10-year median of 8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Quest Laboratories stock overvalued right now?
Quest Laboratories (NSE:QUESTLAB) has a current EV-to-EBIT of 7.49. The current EV-to-EBIT is 7.49, which is 13% below median its 10-year median of 8.60 and 52.6% below the Drug Manufacturers industry median of 15.80. Quest Laboratories' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Quest Laboratories (NSE:QUESTLAB), the current EV-to-EBIT is 7.49 as of Jul. 19, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Quest Laboratories Ltd is engaged in the business of manufacturing pharmaceutical formulations across a broad spectrum, including antibiotics, antimalarials, antispasmodics, anti-inflammatories, antiemetics, respiratory medications, diabetes treatments, antidepressants, and more. It produces various products, comprising ethical drugs, generic drugs, and over-the-counter drugs, and is also available in various forms such as tablets, liquid orals, oral dry powders, oral powders (ORS), ointments, and external liquids, among others. The company operates in a single segment of Drugs and Chemicals.
44GF Score
Get the complete analysis for NSE:QUESTLAB
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QUESTLAB has been successfully added to your 
